tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gao G et al. Rapamycin inhibits hydrogen peroxide-induced loss of vascular contractility. 2011 Am. J. Physiol. Heart Circ. Physiol. pmid:21357511
DuBell WH et al. K(+) currents responsible for repolarization in mouse ventricle and their modulation by FK-506 and rapamycin. 2000 Am. J. Physiol. Heart Circ. Physiol. pmid:10710358
Giordano A et al. Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells. 2012 Am. J. Physiol. Heart Circ. Physiol. pmid:22058159
Fauconnier J et al. Frequency-dependent and proarrhythmogenic effects of FK-506 in rat ventricular cells. 2005 Am. J. Physiol. Heart Circ. Physiol. pmid:15471978
Balasubramaniam R et al. Caffeine-induced arrhythmias in murine hearts parallel changes in cellular Ca(2+) homeostasis. 2005 Am. J. Physiol. Heart Circ. Physiol. pmid:15923307
Sasamori K et al. Cyclic ADP-ribose, a putative Ca2+-mobilizing second messenger, operates in submucosal gland acinar cells. 2004 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:14990397
Lum H et al. Protein phosphatase 2B inhibitor potentiates endothelial PKC activity and barrier dysfunction. 2001 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:11504680
Yaghi A and Sims SM Constrictor-induced translocation of NFAT3 in human and rat pulmonary artery smooth muscle. 2005 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:16055480
Bouvier N et al. Cyclosporine triggers endoplasmic reticulum stress in endothelial cells: a role for endothelial phenotypic changes and death. 2009 Am. J. Physiol. Renal Physiol. pmid:18987109
Ren H et al. Phosphatase inhibition increases AQP2 accumulation in the rat IMCD apical plasma membrane. 2016 Am. J. Physiol. Renal Physiol. pmid:27488997
Thai TL et al. ADP-ribosyl cyclase and ryanodine receptor activity contribute to basal renal vasomotor tone and agonist-induced renal vasoconstriction in vivo. 2007 Am. J. Physiol. Renal Physiol. pmid:17652368
Peherstorfer E et al. Effects of microinjection of synthetic Bcl-2 domain peptides on apoptosis of renal tubular epithelial cells. 2002 Am. J. Physiol. Renal Physiol. pmid:12060601
Axelsson J et al. Scavengers of reactive oxygen species, paracalcitol, RhoA, and Rac-1 inhibitors and tacrolimus inhibit angiotensin II-induced actions on glomerular permeability. 2013 Am. J. Physiol. Renal Physiol. pmid:23657856
Mohebbi N et al. The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins. 2009 Am. J. Physiol. Renal Physiol. pmid:19439519
Cho SG et al. Drp1 dephosphorylation in ATP depletion-induced mitochondrial injury and tubular cell apoptosis. 2010 Am. J. Physiol. Renal Physiol. pmid:20410216
De Miguel C et al. Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease. 2011 Am. J. Physiol. Renal Physiol. pmid:21159736
Rojas-Vega L et al. Increased phosphorylation of the renal Na+-Cl- cotransporter in male kidney transplant recipient patients with hypertension: a prospective cohort. 2015 Am. J. Physiol. Renal Physiol. pmid:26336164
Edinger RS et al. Effect of immunosuppressive agents on glucocorticoid receptor function in A6 cells. 2002 Am. J. Physiol. Renal Physiol. pmid:12110508
Ilori TO et al. Acute calcineurin inhibition with tacrolimus increases phosphorylated UT-A1. 2012 Am. J. Physiol. Renal Physiol. pmid:22205230
Amberg GC et al. Regulation of A-type potassium channels in murine colonic myocytes by phosphatase activity. 2001 Am. J. Physiol., Cell Physiol. pmid:11698261
Ahn HS et al. Calcineurin-independent inhibition of KV1.3 by FK-506 (tacrolimus): a novel pharmacological property. 2007 Am. J. Physiol., Cell Physiol. pmid:17166943
Wang YX et al. FKBP12.6 and cADPR regulation of Ca2+ release in smooth muscle cells. 2004 Am. J. Physiol., Cell Physiol. pmid:14592808
Sans MD and Williams JA Calcineurin is required for translational control of protein synthesis in rat pancreatic acini. 2004 Am. J. Physiol., Cell Physiol. pmid:15044154
Bayguinov O et al. Muscarinic stimulation increases basal Ca(2+) and inhibits spontaneous Ca(2+) transients in murine colonic myocytes. 2001 Am. J. Physiol., Cell Physiol. pmid:11171588
Angus LM et al. Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction. 2005 Am. J. Physiol., Cell Physiol. pmid:15930144
Zhang Y et al. K restriction inhibits protein phosphatase 2B (PP2B) and suppression of PP2B decreases ROMK channel activity in the CCD. 2008 Am. J. Physiol., Cell Physiol. pmid:18184875
Yue G et al. The effect of rapamycin on single ENaC channel activity and phosphorylation in A6 cells. 2000 Am. J. Physiol., Cell Physiol. pmid:10898719
Nam JH et al. Expression of TASK-2 and its upregulation by B cell receptor stimulation in WEHI-231 mouse immature B cells. 2011 Am. J. Physiol., Cell Physiol. pmid:21307343
Nakagawa K et al. Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood TH1/TH2 cell ratios. 2015 Am. J. Reprod. Immunol. pmid:25394810
Nakagawa K et al. Immunosuppressive treatment using tacrolimus promotes pregnancy outcome in infertile women with repeated implantation failures. 2017 Am. J. Reprod. Immunol. pmid:28466977
Saito S et al. Role of Paternal Antigen-Specific Treg Cells in Successful Implantation. 2016 Am. J. Reprod. Immunol. pmid:26706630
Kofod L et al. Endometrial immune markers are potential predictors of normal fertility and pregnancy after in vitro fertilization. 2017 Am. J. Reprod. Immunol. pmid:28440588
Tabata C et al. Calcineurin/NFAT pathway: a novel regulator of parturition. 2009 Am. J. Reprod. Immunol. pmid:19527231
Goldthorpe H et al. Occlusive lung arterial lesions in endothelial-targeted, fas-induced apoptosis transgenic mice. 2015 Am. J. Respir. Cell Mol. Biol. pmid:25879383
Fujiki M et al. Role of T cells in bronchoalveolar space in the development of interstitial pneumonia induced by superantigen in autoimmune-prone mice. 1999 Am. J. Respir. Cell Mol. Biol. pmid:10572064
Deuse T et al. Mechanisms behind local immunosuppression using inhaled tacrolimus in preclinical models of lung transplantation. 2010 Am. J. Respir. Cell Mol. Biol. pmid:19880819
Rolfe FG et al. Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription. 1997 Am. J. Respir. Cell Mol. Biol. pmid:9271313
Yerkovich ST et al. Survival after bronchiolitis obliterans syndrome. 2011 Am. J. Respir. Crit. Care Med. pmid:21325085
Bhorade S et al. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. 2011 Am. J. Respir. Crit. Care Med. pmid:20833822
Koshika T et al. Pretreatment with FK506 improves survival rate and gas exchange in canine model of acute lung injury. 2001 Am. J. Respir. Crit. Care Med. pmid:11208629
Saeki K et al. Endobronchial Lesions of Mycobacterium abscessus Infection in an Immunocompromised Patient. 2017 Am. J. Respir. Crit. Care Med. pmid:28199133
Joshi MS et al. Calcineurin regulates myocardial function during acute endotoxemia. 2006 Am. J. Respir. Crit. Care Med. pmid:16424445
Fauvel H et al. Protective effects of cyclosporin A from endotoxin-induced myocardial dysfunction and apoptosis in rats. 2002 Am. J. Respir. Crit. Care Med. pmid:11850335
Spiekerkoetter E et al. Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. 2015 Am. J. Respir. Crit. Care Med. pmid:26177174
Raofi V et al. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. 1999 Am. J. Surg. pmid:10326847
Tanaka K et al. Living related liver transplantation in children. 1994 Am. J. Surg. pmid:7517649
Li X et al. Increased iNOS-expressing macrophage in long-term surviving rat small-bowel grafts. 2007 Am. J. Surg. pmid:17618815
Rabkin JM et al. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. 2002 Am. J. Surg. pmid:12034401
Jurim O et al. Living-donor liver transplantation at UCLA. 1995 Am. J. Surg. pmid:7538267
Lee KK et al. Successful treatment of ongoing intestinal allograft rejection permits recovery of graft structure and function. 1993 Am. J. Surg. pmid:7678188
Finn L et al. Epstein-Barr virus infections in children after transplantation of the small intestine. 1998 Am. J. Surg. Pathol. pmid:9500771
Randhawa PS et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. 1993 Am. J. Surg. Pathol. pmid:7680544
Minervini MI et al. Acute renal allograft rejection with severe tubulitis (Banff 1997 grade IB). 2000 Am. J. Surg. Pathol. pmid:10757402
Randhawa PS et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. 1996 Am. J. Surg. Pathol. pmid:8772784
Schnitzler M Diabetes mellitus after kidney transplantation in the United States. 2003 Am. J. Transplant. pmid:14510709
Woodward RS et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. 2003 Am. J. Transplant. pmid:12752315
English RF et al. Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. 2002 Am. J. Transplant. pmid:12243498
Kurtz J et al. Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. 2003 Am. J. Transplant. pmid:12814472
Gupta G et al. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. 2015 Am. J. Transplant. pmid:25988397
Silva HT et al. Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. 2013 Am. J. Transplant. pmid:24266969
Suszynski TM et al. Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. 2013 Am. J. Transplant. pmid:23432755
Damon C et al. Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. 2017 Am. J. Transplant. pmid:27597269
Shuker N et al. A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. 2016 Am. J. Transplant. pmid:26714287
Flechner SM et al. Allotransplantation of cryopreserved parathyroid tissue for severe hypocalcemia in a renal transplant recipient. 2010 Am. J. Transplant. pmid:20883540
Benítez CE et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. 2010 Am. J. Transplant. pmid:20883560
Arnold R et al. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. 2013 Am. J. Transplant. pmid:23841745
Hirsch HH et al. BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12. 2016 Am. J. Transplant. pmid:26639422
Bohl DL et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. 2005 Am. J. Transplant. pmid:16095500
Kasahara M et al. Living-donor liver transplantation for hepatoblastoma. 2005 Am. J. Transplant. pmid:16095502
Tan HP et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. 2009 Am. J. Transplant. pmid:19120078
Ashman N et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. 2009 Am. J. Transplant. pmid:19120084
Madeleine MM et al. HPV-related cancers after solid organ transplantation in the United States. 2013 Am. J. Transplant. pmid:24119294
Vongwiwatana A et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. 2004 Am. J. Transplant. pmid:14678043
Bressollette-Bodin C et al. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. 2005 Am. J. Transplant. pmid:15996241
Augustine JJ et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. 2005 Am. J. Transplant. pmid:15996247
Awadalla Y et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. 2004 Am. J. Transplant. pmid:15367226
Luther P and Baldwin D Pioglitazone in the management of diabetes mellitus after transplantation. 2004 Am. J. Transplant. pmid:15575920
Cherukuri A et al. An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. 2012 Am. J. Transplant. pmid:22390816
Dahm F et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. 2004 Am. J. Transplant. pmid:15575921
Pascher A et al. Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. 2015 Am. J. Transplant. pmid:25677074
Okabayashi T et al. Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination. 2011 Am. J. Transplant. pmid:21883903
Hellemons ME et al. Former smoking is a risk factor for chronic kidney disease after lung transplantation. 2011 Am. J. Transplant. pmid:21883906
Zheng H et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. 2003 Am. J. Transplant. pmid:12694072
Montgomery SP et al. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. 2002 Am. J. Transplant. pmid:12118862
Ahsan N et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. 2002 Am. J. Transplant. pmid:12118902
van Hooff JP et al. Glucose metabolic disorder after transplantation. 2007 Am. J. Transplant. pmid:17511670
Silva HT et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. 2007 Am. J. Transplant. pmid:17217442
Heffron TG et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. 2007 Am. J. Transplant. pmid:17511684
Moench C et al. Tacrolimus monotherapy without steroids after liver transplantation--a prospective randomized double-blinded placebo-controlled trial. 2007 Am. J. Transplant. pmid:17511685
Patlolla V et al. Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. 2007 Am. J. Transplant. pmid:17564638
Nijhoff MF et al. Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression. 2016 Am. J. Transplant. pmid:26288226
Pech T et al. Intestinal regeneration, residual function and immunological priming following rescue therapy after rat small bowel transplantation. 2012 Am. J. Transplant. pmid:22974463
McDonald RA et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. 2008 Am. J. Transplant. pmid:18416737
Teuteberg JJ et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. 2010 Am. J. Transplant. pmid:19889126
Turgut F and Akcay A Renal function estimation in cirrhosis. 2009 Am. J. Transplant. pmid:19519814
Irish WD et al. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. 2011 Am. J. Transplant. pmid:21564522
Tricot L et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. 2009 Am. J. Transplant. pmid:19519819
Friman S et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. 2011 Am. J. Transplant. pmid:21564523
Brennan DC et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. 2005 Am. J. Transplant. pmid:15707414
Rogers J et al. Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. 2003 Am. J. Transplant. pmid:14510702